Current Oral Health Reports

, Volume 5, Issue 1, pp 7–12 | Cite as

Periodontal Treatment in Cancer Patients: an Interdisciplinary Approach

  • A. M. Decker
  • L. S. Taichman
  • N. J. D’Silva
  • Russell S. TaichmanEmail author
Systemic Diseases (N Buduneli, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Systemic Diseases


Purpose of Review

Dental care is an essential component in the comprehensive treatment for a cancer patient. As such, a review of the literature was completed to determine the relationships between periodontal and dental care in the cancer patient and provide strategic suggestions.

Recent Findings

Periodontal treatment must be personalized depending on the patient’s current oral health status, systemic status, and progress in treatment. Oral mucositis, periodontal status, and osteonecrosis of the jaw (ONJ) remain periodontal concerns in providing dental care to the cancer patient. Risk factors for development of ONJ include root amputation (OR = 6.64), extraction of a single tooth (OR = 3.7), severe tooth mobility (OR = 3.60), and unclosed wound (OR = 2.51).


Preventive maintenance, oral hygiene instruction, use of fluoride and chlorhexidine are all important therapeutic strategies. If extractions are required in patients who have received bone-modifying drug infusions, flap management and primary wound closure are needed to reduce the risk of complications.


Periodontics Patient care management Neoplasms 


Financial Support

Direct funding was provided by the NIH/NCI PO1-CA093900, the NIH/NCI Tumor Microenvironment Network U54-CA163124 and supplement, Department of Defense W81XWH-14-1-0403, and NIH/NIDCR DE027551 (NJD).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Tsuji K, Shibuya Y, Akashi M, Furudoi S, Yakushijin K, Kawamoto S, et al. Prospective study of dental intervention for hematopoietic malignancy. J Dent Res. 2015;94(2):289–296. These authors completed a prospective study of dental intervention for patients with hematopoietic malignancy, reporting that patients who completed the partial pre-cancer therapy protocol had significantly lower incidence of systemic (15.8 vs. 37.4%) and dental complications (2.9 vs. 34.0%) compared to patients who did not complete any pre-cancer dental therapy. Scholar
  2. 2.
    Toljanic JA, Bedard JF, Larson RA, Fox JP. A prospective pilot study to evaluate a new dental assessment and treatment paradigm for patients scheduled to undergo intensive chemotherapy for cancer. Cancer. 1999;85(8):1843–8.<1843::AID-CNCR26>3.0.CO;2-R.CrossRefPubMedGoogle Scholar
  3. 3.
    Schuurhuis JM, Stokman MA, Roodenburg JL, Reintsema H, Langendijk JA, Vissink A, et al. Efficacy of routine pre-radiation dental screening and dental follow-up in head and neck oncology patients on intermediate and late radiation effects. A retrospective evaluation. Radiother Oncol. 2011;101(3):403–9. Scholar
  4. 4.
    Borowski B, Benhamou E, Pico J, Laplanche A, Margainaud J, Hayat M. Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: a randomised controlled trial comparing two protocols of dental care. Eur J Cancer B Oral Oncol. 1994;30(2):93–7. Scholar
  5. 5.
    Peterson D. Pretreatment strategies for infection prevention in chemotherapy patients. NCI monographs: a publication of the National Cancer Institute. 1989;9:61–71.Google Scholar
  6. 6.
    Greenberg MS, Cohen SG, McKitrick JC, Cassileth PA. The oral flora as a source of septicemia in patients with acute leukemia. Oral Surgery, Oral Medicine, Oral Pathology. 1982;53(1):32–6. Scholar
  7. 7.
    Hong CH, Hu S, Haverman T, Stokman M, Napeñas JJ, Bos-den Braber J et al. A systematic review of dental disease management in cancer patients. Support Care Cancer. 2018;26(1):155–174.Google Scholar
  8. 8.
    Raber-Durlacher JE, Epstein JB, Raber J, van Dissel JT, van Winkelhoff A, Guiot HF, et al. Periodontal infection in cancer patients treated with high-dose chemotherapy. Support Care Cancer. 2002;10(6):466–73. Scholar
  9. 9.
    • Vozza I, Caldarazzo V, Polimeni A, Ottolenghi L. Periodontal disease and cancer patients undergoing chemotherapy. Int Dent J. 2015;65(1):45–48. These authors reported the prevalence of periodontal disease in a population with malignant solid tumors submitted to chemotherapy was 35.2% at the time of their cancer diagnosis, and periodontal treatment was effective in reducing plaque index, bleeding on probing, pocket depth, and maintaining attachment loss as these patients underwent chemotherapy. Scholar
  10. 10.
    Philipone E, Yoon AJ. Oral soft tissue manifestations of hematologic abnormalities and diseases. Oral Pathology in the Pediatric Patient. Springer. 2017. p 129–34.Google Scholar
  11. 11.
    Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;1999(341):1051–62.CrossRefGoogle Scholar
  12. 12.
    Epstein J, Page J, Anderson G, Spinelli J. The role of an immunoperoxidase technique in the diagnosis of oral herpes simplex virus infection in patients with leukemia. Diagn Cytopathol. 1987;3(3):206–9. Scholar
  13. 13.
    Bressan V, Stevanin S, Bianchi M, Aleo G, Bagnasco A, Sasso L. The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: a systematic review. Cancer Treat Rev. 2016;45:105–19. Scholar
  14. 14.
    Dechaphunkul T, Martin L, Alberda C, Olson K, Baracos V, Gramlich L. Malnutrition assessment in patients with cancers of the head and neck: a call to action and consensus. Crit Rev Oncol Hematol. 2013;88(2):459–76. Scholar
  15. 15.
    Ogama N, Suzuki S, Umeshita K, Kobayashi T, Kaneko S, Kato S, et al. Appetite and adverse effects associated with radiation therapy in patients with head and neck cancer. Eur J Oncol Nurs. 2010;14(1):3–10. Scholar
  16. 16.
    Ogama N, Suzuki S. Adverse effects and appetite suppression associated with particle beam therapy in patients with head and neck cancer. Jpn J Nurs Sci. 2012;9(1):28–37. Scholar
  17. 17.
    • Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M et al. A multicenter retrospective study of the risk factors associated with medication-related osteonecrosis of the jaw after tooth extraction in patients receiving oral bisphosphonate therapy: can primary wound closure and a drug holiday really prevent MRONJ? Osteoporos Int. 2017:1–9. These authors completed a non-randomized, multi-centered retrospective study including 1175 patients, to determine the significant risk factors for ONJ in patients taking oral bisphosphonates. Overall, the study reported a 1.7% frequency of post-extraction ONJ in patients taking oral bisphosphonates. The study determined that concurrent disease status (i.e., cancer and diabetes) was not significant. However, local treatment factors including root amputation (OR = 6.64), extraction of a single tooth (OR = 3.7), severe tooth mobility (OR = 3.60), and unclosed wound (OR = 2.51) significantly contributed risk to the development of ONJ. Google Scholar
  18. 18.
    Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221–7. Scholar
  19. 19.
    Rennert G, Pinchev M, Gronich N, Saliba W, Flugelman A, Lavi I, et al. Oral bisphosphonates and improved survival of breast cancer. Clin Cancer Res. 2017;23(7):1684–9. Scholar
  20. 20.
    Vale CL, Burdett S, Rydzewska LH, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–56. Scholar
  21. 21.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–82. Scholar
  22. 22.
    Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22. Scholar
  23. 23.
    • Vehmanen L, Suojanen J, Kontio R, Utriainen T, Blomqvist C. High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients. Acta Oncol. 2017;56(1):104–106. These authors completed a case series with 254 men with castrate-resistant prostate cancer and treated with zolendronic acid, denosumab, or both, who also received dental extractions by oral and maxillofacial surgeons. In total, 29 out of 254 men (11.4%) developed ONJ. Of the patients who developed ONJ, 2 received only zolendronic acid, 9 received only denosumab, and 18 received both zolendronic acid and denosumab. Seventeen of the 29 ONJ cases had chronic disability of the jaw or jaw necrosis that continued until the death of the patient. Scholar
  24. 24.
    Lee IJ, Koom WS, Lee CG, Kim YB, Yoo SW, Keum KC, et al. Risk factors and dose–effect relationship for mandibular osteoradionecrosis in oral and oropharyngeal cancer patients. Int J Radiat Oncol Biol Phys. 2009;75(4):1084–91. Scholar
  25. 25.
    Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41(5):283–8. Scholar
  26. 26.
    • Owosho AA, Tsai CJ, Lee RS, Freymiller H, Kadempour A, Varthis S, et al. The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): the Memorial Sloan Kettering Cancer Center experience. Oral Oncol. 2017;64:44–51. These authors completed a case-control study at the Memorial Sloan Kettering Cancer Center. The authors determined the prevalence of ORN to be 4.3% during a median follow-up time of 52.5 months. Furthermore, the authors stated that patients treated for oropharyngeal cancer were prone to develop ORN earlier compared to patients with oral cavity cancer. In addition, these authors reported that poor periodontal status, history of alcohol use, and radiation dose were significant risk factors. Scholar
  27. 27.
    Chen JA, Wang CC, Wong YK, Wang CP, Jiang RS, Lin JC, et al. Osteoradionecrosis of mandible bone in patients with oral cancer—associated factors and treatment outcomes. Head & neck. 2016;38(5):762–8. Scholar
  28. 28.
    • Dieleman F, Phan T, van den Hoogen F, Kaanders J, Merkx M. The efficacy of hyperbaric oxygen therapy related to the clinical stage of osteoradionecrosis of the mandible. Int J Oral Maxillofac Surg. 2017;46(4):428–433. These authors completed a retrospective study and reported that the cause of ORN was most commonly extractions after radiation therapy (22%) or prosthetics (22%) followed by periodontal disease (11%) and tumor-related surgery (11%). Interestingly, treatment with hyperbaric oxygen is only significantly effective for lower stages of ORN, while higher stages of ORN still require segmental resection of the affected structure. Scholar
  29. 29.
    Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol. 2010;28(23):3784–96. Scholar
  30. 30.
    Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol. 2008;26(7):1051–7. Scholar
  31. 31.
    Taichman LS, Van Poznak CH, Inglehart MR. Self-reported oral health and quality of life of postmenopausal breast cancer survivors on aromatase inhibitors and women without cancer diagnoses: a longitudinal analysis. Support Care Cancer. 2016;24(11):4815–24. Scholar
  32. 32.
    NIDCR. Cancer Treatment and Oral Health. 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • A. M. Decker
    • 1
  • L. S. Taichman
    • 2
  • N. J. D’Silva
    • 1
    • 3
  • Russell S. Taichman
    • 1
    Email author
  1. 1.Department of Periodontics and Oral MedicineUniversity of Michigan School of DentistryAnn ArborUSA
  2. 2.Department of Family MedicineUniversity of Michigan School of MedicineAnn ArborUSA
  3. 3.Department of PathologyUniversity of MichiganAnn ArborUSA

Personalised recommendations